['spondyloarthritis']
['ixekizumab', 'placebo', 'adalimumab']

        Inclusion Criteria:

          -  Are ambulatory.

          -  Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined
             radiographically according to the modified New York criteria.

          -  Participants have a history of back pain ≥3 months with age at onset <45 years.

          -  In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
             drugs (for duration 4 weeks) or cannot tolerate NSAIDS.

          -  If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.

          -  Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have total ankylosis of the spine.

          -  Have received any prior, or are currently receiving, treatment with biologics, tumor
             necrosis factor inhibitors or other immunomodulatory agents.

          -  Have recently received a live vaccine within 12 weeks or have had a vaccination with
             Bacillus Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.
      